Form 4: Rachel Humphrey Reports Acquisition and Disposal of Pyxis Oncology Stock
SEC Form 4 Filing
Director Rachel Humphrey reports acquiring 38,741 shares of Pyxis Oncology stock and disposing of 96,805 shares on March 26, 2024.
Summary
- On March 26, 2024, Rachel Humphrey, a director of Pyxis Oncology, acquired 38,741 shares of common stock.
- The acquisition price was $0 per share.
- On the same day, Humphrey disposed of 96,805 shares of common stock.
- Following these transactions, Humphrey beneficially owns 96,805 shares of Pyxis Oncology.
- The reported transactions also involve restricted stock units that vest 100% on the first anniversary of the grant date, contingent upon continued service.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by a company insider; it doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the biotechnology industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholder sentiment, depending on how the market interprets insider activity.
Key Dates
| Date | Description |
|---|---|
| 03/26/2024 | Date of stock acquisition and disposal. |
| 03/28/2024 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.